Argus upgraded Teva to Buy from Hold.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- FTC sends Teva civil investigative demand over patents, WaPo reports
- Federal Court allows Vanda’s HETLIOZ patent lawsuit to proceed
- Teva announces data from fourth interim analysis of PEARL study of AJOVY
- Teva price target raised to $23 from $19 at Jefferies
- Teva’s agreement with the ITA has no impact on 2024 financial outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue